ArticleOncogenesis2026
Lung adenocarcinoma cell-derived lactate activates CAFs to promote macrophage M2 polarization via exosomal miR-214-5p.
Article in Oncogenesis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer-associated fibroblasts (CAFs) are key components of the tumor microenvironment that can drive cancer progression and immune evasion. Here, we identify a novel pathway in which lactate produced by lung adenocarcinoma (LUAD) cells activates normal fibroblasts into CAFs, inducing high expression of microRNA miR-214-5p. The CAFs secrete miR-214-5p via exosomes, which in turn polarizes tumor-associated macrophages (TAMs) toward the immunosuppressive M2 phenotype. Mechanistically, exosomal miR-214-5p targets the transcriptional repressor BHLHE41 in macrophages, relieving its inhibition on M2-polarization genes. We further demonstrate that lactate accumulation epigenetically upregulates miR-214-5p in CAFs by increasing histone H3 lysine 9 lactylation (H3K9la) at the DNM3OS/miR-214 gene locus, independently of the lactate receptor GPR81. Lactate also enhances the loading of miR-214-5p into exosomes by inducing lactylation of the RNA-binding protein YBX1, which binds miR-214-5p and facilitates its exosomal export. In a mouse co-implantation model of LUAD, pharmacological blockade of tumor lactate production (LDH inhibition) reduced CAF activation, TAM M2 polarization, miR-214-5p levels, and tumor growth. Our findings uncover a lactate-driven CAF-TAM signaling axis via exosomal miR-214-5p, highlighting potential therapeutic targets to counteract tumor immune evasion in lung adenocarcinoma.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.